Wednesday, January 22, 2020
Home Authors Posts by Editor / Curator

Editor / Curator

178 POSTS 0 COMMENTS
Oramed, Biotech Stock REview
Biotech News

Oramed (ORMP) $5.24, Focused on Pill Form Insulin. Is China First?

Editor / Curator -
Mitesco, Biotech Stock Review
Incubator

Medtech Incubator True Nature | Mitesco (TNTY) Adds Another Heavy Hitter...

Editor / Curator -
video
Biotech News

Candida Auris: Hospitals mobilize to fight the deadly infection (Video). More...

Editor / Curator -
All News

Citius Pharma (CTXR), Fortress Biotech (FBIO) and True Nature (TNTY) Significantly...

Editor / Curator -
All News

Apple’s Second Chance at Romance. One That Got Away, Twice!

Editor / Curator -
Julie R Smith, True Nature, Mitesco
Interview

True Nature|Mitesco President & COO, Julie Smith Interview.

Editor / Curator -
Biotech News

True Nature|Mitesco (TNTY). Coverage Report Issued.

Editor / Curator -
Biotech News

Bellus Health (BLUSF) to Present at SF Stock & Bond...

Editor / Curator -
Biotech Stock Review,
Telehealth

Premier Health (PHGRF) Announces Definitive Agreement to Acquire Livecare.

Editor / Curator -
Internet Stock Review, Biotech Stock Review
Featured

.

Editor / Curator -
123...18Page 1 of 18

Latest article

Oramed, Biotech Stock REview

Oramed (ORMP) $5.24, Focused on Pill Form Insulin. Is China First?

Biotech News Editor / Curator -
New technology could revolutionize market of 500 million diabetes patients (i24 News).
Mitesco, Biotech Stock Review

Medtech Incubator True Nature | Mitesco (TNTY) Adds Another Heavy Hitter to Board.

Incubator Editor / Curator -
True Nature Holding, Inc. DBA Mitesco, Inc. Adds Distinguished Healthcare Executive to Board of Directors.
video

Candida Auris: Hospitals mobilize to fight the deadly infection (Video). More Videos Below.

Biotech News Editor / Curator -
https://youtu.be/hnqFdKSG6-A Auris all over the room, even on the ceiling?.
The Internet Stock Review is one of Wall Streets oldest newsletters covering internet technology having launched in 1999. The Biotech Stock Review is rather old too, having launched in 2002. We make our money by purchasing stock with our services, so the better our client stocks do, the better we all do. And when we're wrong, we feel the pain too! See our research reports for important disclaimer details. Content is provided by Institutional Analyst Inc., the website is managed by Revelers.IO Media Group Inc. To see if your Company qualifies for coverage, call 310-594-8062
Contact us: roland@institutionalanalyst.com
© Managed by Revelers.IO Media Group Inc.